Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • SillyPoint
    Member
    • May 2008
    • 39

    #1

    ONT error model and quality scoring

    Regarding ONT's new technology, I think I heard the following over the last few days (please correct if I've mis-heard):
    • Error rate is 4% today, targeting 1% by release.
    • Predominant error is a deletion.
    • Output (e.g., from MinION) is in fastq format.

    4% of what? Given an error model including deletions, one possible interpretation is that there is a 4% chance that a given base will be missed. ONT, is that what you mean?

    More to the point: What observable aspects of the process are used in computing quality scores? We've been shown (sort of) how current traces can be converted into basecalls. What residue of that information is used in generating confidence estimates? If we knew that, we could better understand what use we can make of the scores.

    In any case, a fastq format doesn't seem appropriate. This isn't the Illumina error model, where you want to quantify by Q score the likelihood that a basecall at a given position is wrong. If I see a score of Q14 at some position in an ONT fastq file, does that mean there's a 4% chance that (1) the base was called wrong, (2) a base was missed following, or (3) prior to this position? How do I encode the case of miscall-plus-two-deletions at a given position?

    --TS

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 10:13 AM
0 responses
10 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
19 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
17 views
0 reactions
Last Post SEQadmin2  
Working...